-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Dapagliflozin + Sitagliptin) in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Dapagliflozin + Sitagliptin) in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Dapagliflozin + Sitagliptin) in Type 2 Diabetes Drug Details:...
-
Product Insights
Idiopathic (Essential) Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Drugs In Development, 2023’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-534 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PM-534 in Solid Tumor Drug Details: PM-534 is under development for the treatment of advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Chordoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MVXONCO-1 in Chordoma Drug Details: MVXONCO-1 is under development for the treatment of lung carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KDF-2001 in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KDF-2001 in Type 2 Diabetes Drug Details: KDF-2001 is under development for the treatment of...